A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilié PG, Davis JW.
Hahn AW, et al. Among authors: zhang m.
BJU Int. 2024 Jun 4. doi: 10.1111/bju.16414. Online ahead of print.
BJU Int. 2024.
PMID: 38837608